SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                   FORM 10-QSB

(Mark One)
         [X]      Quarterly report under Section 13 or 15(d) of the Securities
                  Exchange Act of 1934

                  FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2002

         [ ]      Transition report under Section 13 or 15(d) of the Exchange
                  Act

             For the transition period from __________ to __________

                         Commission file number 0-29489


                                MALACOLOGY, INC.
         --------------------------------------------------------------
        (Exact Name of Small Business Issuer as Specified in Its Charter)

          NEVADA                                                 33-0850627
-------------------------------                              -------------------
(State or Other Jurisdiction of                                (IRS Employer
Incorporation or Organization)                               Identification No.)

                        1101 Channelside Drive, Suite 241
                              Tampa, Florida 33602
                     --------------------------------------
                    (Address of Principal Executive Offices)


                                 (813) 864-3900
                 ----------------------------------------------
                (Issuer's Telephone Number, Including Area Code)


                                       N/A
               --------------------------------------------------
              (Former Name, Former Address and Former Fiscal Year,
                          If changed since Last Report)

         Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

                                 Yes [X] No [ ]

         State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date: As of August 13, 2002 there
were 1,000,000 shares of common stock issued and outstanding, par value $0.001,
and no shares of preferred stock are issued and outstanding.

<PAGE>

                                MALACOLOGY, INC.

                                      INDEX
                                                                          Page

Part  I  Financial Information

Item  1. Financial Statements

         Consolidated balance sheets as of June 30, 2002
         (unaudited) and December 31, 2001                                 3

         Consolidated statements of operations for the three and
         six months ended June 30, 2002 and 2001, and for the
         period from inception, April 9, 1998, through June 30, 2002
         (unaudited)                                                       4

         Consolidated statements of cash flows for the six months
         ended June 30, 2002 and 2001, and for the period from
         inception, April 9, 1998, through June 30, 2002 (unaudited)       5

         Notes to consolidated financial statements                      6-9

Item  2. Management's Discussion and Analysis or Plan of Operation        10

Part  II Other Information                                                14

Item  1. Legal Proceedings                                                14

Item  2. Changes in Securities                                            14

Item  3. Defaults Upon Senior Securities                                  14

Item  4. Submission of Matters to a Vote of Security Holders              14

Item  5. Other Information                                                14

Item  6. Exhibits and Reports on Form 8-K                                 14

                                       2
<PAGE>
<TABLE>
<CAPTION>
                                        MALACOLOGY, INC.
                                (A Development Stage Enterprise)

                                   Consolidated Balance Sheets

                                             ASSETS

                                                                                  June 30, 2002    December 31, 2001
                                                                                   (unaudited)
                                                                                  -------------    ----------------
<S>                                                                               <C>              <C>
Cash                                                                              $         174    $          7,145
Other current assets                                                                        188              17,130
                                                                                  -------------    ----------------

           Total current assets                                                             362              24,275

Equipment, net of accumulated depreciation of $320 and $0, respectively                   1,603               1,923
                                                                                  -------------    ----------------
           Total assets                                                           $       1,965    $         26,198

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Accrued expenses                                                                  $     238,646    $              -
Advances from officer                                                                   130,840             123,740
Convertible notes payable                                                                11,475              11,475
                                                                                  -------------    ----------------

           Total current liabilities                                                    380,961             135,215
                                                                                  -------------    ----------------

Convertible notes payable                                                               150,000             100,000
                                                                                  -------------    ----------------

           Total liabilities                                                            530,961             235,215
                                                                                  -------------    ----------------

Commitments

Stockholders' equity (deficit)
   Preferred stock, $0.001 par value; 2,000,000 shares authorized; no
      shares issued and outstanding                                                           -                   -
   Common stock, $0.001 par value; 20,000,000 shares authorized;
      1,000,000 shares issued and outstanding                                             1,000               1,000
   Deficit accumulated during the development stage                                    (529,996)           (210,017)
                                                                                  -------------    -----------------

           Total stockholders' equity (deficit)                                        (528,996)           (209,017)
                                                                                  -------------    ----------------

           Total liabilities and stockholders' equity (deficit)                   $       1,965    $         26,198
                                                                                  =============    ================


                               See accompanying notes to consolidated financial statements

                                                          3
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
                                                 MALACOLOGY, INC.
                                         (A Development Stage Enterprise)

                                      Consolidated Statements of Operations
                                                   (Unaudited)


                                                                                                                 Period From
                                                                                                                  Inception
                                                    Three Months                        Six Months              April 9, 1998
                                                       Ended                               Ended                   Through
                                                      June 30,                            June 30,                 June 30,
                                               2002             2001              2002                2001           2002
                                            -----------       ---------         ----------          ---------     ----------
<S>                                         <C>               <C>               <C>                 <C>           <C>
Consulting fees                             $   (29,117)      $       -         $  (87,871)         $       -     $ (244,447)

General and administrative expenses            (117,592)           (367)          (232,108)            (1,925)      (291,966)
                                            -----------       ---------         ----------          ---------     ----------

Loss before extraordinary item              $  (146,709)      $    (367)        $ (319.979)         $  (1,925)    $ (536,413)

Extraordinary item:
Gain on forgiveness of related party
  payable                                             -               -                  -                  -          6,417
                                            -----------       ---------         ----------          ---------     ----------


Net loss                                    $  (146,709)      $    (367)        $ (319,979)         $  (1,925)    $ (529,996)
                                            ===========       =========         ==========          =========     ==========

Weighted average number of common
  Shares outstanding                          1,000,000       1,000,000          1,000,000          1,000,000      1,000,000
                                            ===========       =========         ==========          =========     ==========


Net loss per share                          $     (0.15)      $   (0.00)        $    (0.32)         $   (0.00)    $    (0.53)
                                            ===========       =========         ==========          =========     ==========


                                See accompanying notes to consolidated financial statements

                                                            4
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
                                                 MALACOLOGY, INC.
                                         (A Development Stage Enterprise)

                                      Consolidated Statements of Cash Flows
                                                   (Unaudited)


                                                                                                    Period From
                                                                                                     Inception,
                                                            Six Months         Six Months          April 9, 1998,
                                                               Ended              Ended               Through
                                                             June 30,            June 30,             June 30,
                                                               2002                2001                 2002
                                                          ---------------    ----------------     -----------------
<S>                                                       <C>                <C>                  <C>
Cash flows from operating activities
   Net loss                                               $      (319,979)   $         (1,925)    $        (529,996)
   Adjustments to reconcile net loss to net cash used
      by operating activities
         Depreciation expense                                         320                   -                   320
        Issuance of common stock for services                           -                   -                 1,000
        Decrease (increase) in other current assets                16,942                   -                  (188)
        Increase in accrued expenses                              238,646                   -               238,646
        (Decrease) increase in payable to
            related party                                               -               1,925                     -
                                                          ---------------    ----------------     -----------------

               Net cash used by operating
                 activities                                       (64,071)                  -              (290,218)
                                                          ---------------    ----------------     -----------------

Cash flows from investing activities
    Acquisition of equipment                                            -                   -                (1,923)
                                                          ---------------    ----------------     -----------------

Cash flows from financing activities
   Advances from officer                                            7,100                   -               130,840
   Proceeds from convertible notes payable                         50,000                   -               161,475
                                                          ---------------    ----------------     -----------------

               Net cash provided by financing
                 activities                                        57,100                   -               292,315
                                                          ---------------    ----------------     -----------------

Net (decrease) increase in cash                                    (6,971)                  -                   174

Cash, beginning of period                                           7,145                   -                     -
                                                          ---------------    ----------------     -----------------

Cash, end of period                                       $           174    $              -     $             174
                                                          ===============    ================     =================

Supplemental disclosure of cash flow information:

   Cash paid during the period for:
      Interest                                            $             -    $              -     $               -
                                                          ===============    ================     =================
      Income taxes                                        $             -    $              -     $               -
                                                          ===============    ================     =================

                               See accompanying notes to consolidated financial statements

                                       5
</TABLE>
<PAGE>

                                MALACOLOGY, INC.
                        (A Development Stage Enterprise)

                   Notes to Consolidated Financial Statements

1.       Basis of Presentation, Capital Structure, and Significant Accounting
         Policies

         Basis of Presentation

         Malacology, Inc. (A Development Stage Enterprise) (the "Company") was
         incorporated on April 9, 1998 under the laws of the State of Nevada.
         The Company intends to develop operating opportunities through business
         combinations or mergers. To date, the Company has not conducted any
         significant operations, and its activities have focused primarily on
         organizational efforts, corporate compliance matters and locating
         potential merger candidates. Since the Company has not yet commenced
         any principal operations, and has not yet earned significant revenues,
         the Company is considered to be a development stage enterprise as of
         June 30, 2002.

         West Wing Holdings Acquisitions, Inc. ("West Wing") was incorporated in
         the State of Florida on December 14, 2001 as a wholly owned subsidiary
         of the Company. West Wing was formed with the objective of providing
         value added, low cost telecommunication services in foreign markets.
         West Wing has conducted no operations to date, and is a nonoperating
         shell company.

         The accompanying consolidated financial statements include the accounts
         of the Company and West Wing from the date of its formation.

         The accompanying unaudited consolidated financial statements have been
         prepared in accordance with accounting principles generally accepted in
         the United States of America for interim financial information and the
         instructions to Form 10-QSB. Accordingly, they do not include all the
         information and footnotes required by accounting principles generally
         accepted in the United States of America for complete financial
         statements. In the opinion of management, the interim financial
         statements include all adjustments considered necessary for a fair
         presentation of the Company's financial position, results of operations
         and cash flows for the three months and six months ended June 30, 2002.
         These statements are not necessarily indicative of the results to be
         expected for the full fiscal year. These statements should be read in
         conjunction with the financial statements and notes thereto included in
         the Company's Form 10-KSB for the year ended December 31, 2001 as filed
         with the Securities and Exchange Commission.

                                       6
<PAGE>

                                MALACOLOGY, INC.
                        (A Development Stage Enterprise)

                   Notes to Consolidated Financial Statements

1.       Basis of Presentation, Capital Structure, and Significant Accounting
         Policies (continued)

         Capital Structure

         On April 10, 1998, the Company's Board of Directors approved the
         issuance of 1,000,000 shares of common stock to the Company's founders
         for services which were valued at a nominal amount approximating fair
         value ($1,000 recorded as general and administrative expenses in the
         accompanying statement of operations). Of these shares, 824,500 shares
         were issued to two officers of the Company, and as of December 31,
         2000, such shares were owned by one officer.

         In October 2001, the Company's then majority stockholder and sole
         officer and director and one other former stockholder sold 970,000
         shares of the Company's common stock to Contract Consultants
         International, Inc. ("CCI") for cash of $25,000. CCI sold the same
         970,000 shares of the Company's common stock to the Company's current
         President and sole director for $100,000 cash. Such transactions
         resulted in a change in control of the Company.

         The Company also granted stock options pursuant to an employment
         agreement that is described in Note 3.

         Going Concern and Management's Plans

         The Company has not commenced significant operations and has limited
         financial and other resources. Such matters raise substantial doubt
         about the Company's ability to continue as a going concern.
         Management's plans with respect to these conditions are to search for
         additional sources of debt and/or equity financing and new operating
         opportunities through business combinations or mergers. In the interim,
         the Company will require minimal overhead, and key administrative and
         management functions will be provided by consultants and stockholders.
         Accordingly, the accompanying financial statements have been presented
         under the assumption that the Company will continue as a going concern.

                                       7
<PAGE>

                                MALACOLOGY, INC.
                        (A Development Stage Enterprise)

                   Notes to Consolidated Financial Statements

1.       Basis of Presentation, Capital Structure, and Significant Accounting
         Policies (continued)

         Management Estimates

         The preparation of financial statements in conformity with accounting
         principles generally accepted in the United States of America requires
         management to make estimates and assumptions that affect the reported
         amounts of assets and liabilities, and disclosure of contingent assets
         and liabilities at the date of the financial statements, and the
         reported amounts of revenues and expenses during the reporting period.
         Actual results could differ from those estimates.

2.       Advances from Officer

         As of June 30, 2002, the Company has received advances from its
         President and sole director in the aggregate amount of $130,840. As of
         the date of this report, such advances are not subject to formal,
         written agreements, have no stated repayment terms, do not bear
         interest, and are not collateralized.

3.       Commitments

         Employment Agreements

         The Company has employment agreements with its President, who is the
         Company's sole director and majority stockholder, and its Chief
         Financial Officer. The agreements provide for minimum annual salaries
         of $250,000 and $150,000 respectively and are for terms ranging for two
         to five years. The agreements also provide for minimum severance
         payments to the officers equal to amounts ranging from $37,500 to
         $750,000 in the aggregate. The Company's President is entitled to
         receive annual bonuses equal to 60% of his then annual salary, provided
         that such bonus will be reduced to the extent that it exceeds the
         Company's net profit (as defined).

         Effective June 10, 2002, Mr. Kenneth O'Rorke, the Company's Chief
         Financial Officer, tendered his resignation to the Company. In
         connection with his resignation, the Company agreed to issue Mr.
         O'Rorke twenty-five thousand (25,000) shares of the Company's Common
         Stock and a stock option exercisable for three (3) years to purchase
         125,000 shares of the Company's Common Stock at a cost of $1.50 per
         share. The issuance of the shares and option is contingent upon the
         Company's acquisition of certain assets from an unrelated third party.

         As of June 30, 2002, the Company has accrued salaries payable of
         $112,850, and such amount is included in accrued expenses in the
         accompanying consolidated balance sheet.

                                       8
<PAGE>

                                MALACOLOGY, INC.
                        (A Development Stage Enterprise)

                   Notes to Consolidated Financial Statements

         Consulting Agreement

         The Company had a one-year consulting agreement, maturing September
         2002, which requires payments of $15,000 per month and can be
         terminated by either party with thirty days written notice. The
         consulting agreement also provided an option to participate in a
         convertible debenture offering whereby $1,200 of convertible notes
         payable were issued by the Company (convertible into 1,200,000 shares
         of the Company's common stock). Effective May 31, 2002, the Company
         terminated this consulting agreement.

4.       Subsequent events

         On July 31, 2002, the Company paid off the above mentioned convertible
         notes payable in the amount $1,200. The Company has accrued consulting
         fees in the amount of $66,212.06 to Apogee Business Consultants, LLC.
         On August 1, 2002, Apogee Business Consultants, LLC has agreed to
         forgive their accrued consulting fees.

         On July 26, 2002, the company paid off an additional convertible notes
         payable in the amount of $25.00 plus $1.00 in accrued interest.

                                       9
<PAGE>

Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

         The following discussion contains certain forward-looking statements
that are subject to business and economic risks and uncertainties, and the
Company's actual results could differ materially from those forward-looking
statements. The following discussion regarding the financial statements of the
Company should be read in conjunction with the financial statements and notes
thereto.

BACKGROUND OF THE COMPANY

         The Company was organized under the Laws of the State of Nevada, on
April 9,1998, as a blank check or shell company whose primary purpose is to
engage in a merger with, or acquisition of one or a small number of private
firms. Such firms are expected to be private corporations, partnerships or sole
proprietorships. From inception through the present time, the primary activity
of the Company has been directed towards organizational efforts, compliance
matters and locating potential merger candidates.

         On October 22, 2001, M. Richard Cutler, at that time a principal
shareholder of the Company and the Company's sole officer and director and Vi
Bui, at that time a principal shareholder of the Company, sold an aggregate of
970,000 shares of the Company's common stock to Contracts Consultants
International, Inc. ("CCI"), a Florida corporation. Simultaneously therewith,
CCI sold those same 970,000 shares to Mr. Vivek Rao. These shares represent 97%
of the issued and outstanding shares of the Company. As a result of the above
described transactions, Vivek R. Rao became the "control person" of the Company
as that term is defined in the Securities Act of 1933, as amended (the "Act").
Simultaneously with these transactions, the board of directors nominated Vivek
R. Rao to the board of directors and all former officers and directors resigned,
thereby leaving Mr. Rao the Company's sole director. Vivek R. Rao was then
appointed the Company's CEO, President, Secretary and Treasurer.

         In December 2001, we formed West Wing Holdings Acquisitions, Inc.
("West Wing"), a Florida corporation as a wholly owned subsidiary. West Wing
planned to enter the telecommunications industry through the acquisition of
certain assets in Eastern Europe. The Company was unable to complete the
acquisition of the targeted assets and is currently seeking out other
opportunities within and outside the telecommunications industry. Accordingly,
the Company is still a "blank check" or "shell" company despite the expenditure
of significant resources in an effort to acquire telecommunications assets in
Eastern Europe through its West Wing subsidiary. At present, the Company has no
business opportunities under contemplation for acquisitions.

GENERAL OVERVIEW

         The Company's activities since inception have been limited to
organizational matters, compliance efforts and locating potential merger
candidates, and the Company has not engaged in any operating activity since its
inception.

                                       10
<PAGE>

         The Company has registered its Common Stock on a Form 10-SB
registration statement filed pursuant to the Securities Exchange Act of 1934
(the Exchange Act) and Rule 12(g) thereof. The Company files with the Securities
and Exchange Commission periodic reports under Rule 13(a) of the Exchange Act,
including quarterly reports on Form 10-QSB and annual reports on Form 10-KSB.

         The Company was formed to engage in a merger with or acquisition of an
unidentified foreign or domestic private company which desires to become a
reporting (public) company whose securities are qualified for trading in the
United States secondary market. The Company meets the definition of a blank
check company contained in Section 7(b)(3) of the Securities Act of 1933, as
amended.

         Management believes that there are perceived benefits to being a
reporting company with a class of publicly-traded securities which may be
attractive to foreign and domestic private companies.

         These benefits are commonly thought to include (1) the ability to use
registered securities to make acquisition of assets or businesses; (2) increased
visibility in the financial community; (3) the facilitation of borrowing from
financial institutions; (4) improved trading efficiency; (5) shareholder
liquidity; (6) greater ease in subsequently raising capital; (7) compensation of
key employees through options for stock for which there is a public market; (8)
enhanced corporate image; and, (9) a presence in the United States capital
market.

         A private company which may be interested in a business combination
with the Company may include (1) a Company for which a primary purpose of
becoming public is the use of its securities for the acquisition of assets or
businesses; (2) a company which is unable to find an underwriter of its
securities or is unable to find an underwriter of securities on terms acceptable
to it; (3) a company which wishes to become public with less dilution of its
Common Stock than would occur normally upon an underwriting; (4) a company which
believes that it will be able to obtain investment capital on more favorable
terms after it has become public; (5) a foreign company which may wish an
initial entry into the United States securities market; (6) a special situation
company, such as a company seeking a public market to satisfy redemption
requirements under a qualified Employee Stock Option Plan; and, (7) a company
seeking one or more of the other benefits believed to attach to a public
company.

         The Company is authorized to enter into a definitive agreement with a
wide variety of private businesses without limitation as to their industry or
revenues. It is not possible at this time to predict with which private company,
if any, the Company will enter into a definitive agreement or what will be the
industry, operating history, revenues, future prospects or other characteristics
of that company.

         As of the date hereof, Management has not made any final decision
concerning, and has not entered into any agreements for, a business combination.
When any such agreement is reached or other material fact occurs, the Company
will file notice of such agreement or fact with the Securities and Exchange
Commission on Form 8-K. Persons reading this Form 10-QSB are advised to see if
the Company has subsequently filed a Form 8-K.

                                       11
<PAGE>

         There is no trading market for our common stock and no market may ever
exist for the Company's common stock. The Company plans to assist broker-dealers
in complying with Rule 15c2-11 of the Securities Exchange Act of 1934, as
amended, so that such brokers can trade the Company's common stock in the
Over-The-Counter Electronic Bulletin Board (the "Bulletin Board") and to attempt
to list the Company's common stock on the "Bulletin Board Exchange" ("BBX")
proposed by the Nasdaq Stock Market, if it replaces the Bulletin Board. There
can be no assurance to investors that any broker-dealer will actually file the
materials required in order for such Bulletin Board trading to proceed or that
the Company will be able to list its common stock on the BBX.

         In 2003, subject to approval of the Securities and Exchange Commission,
The NASDAQ Stock Market intends to phase out the OTC Bulletin Board, and replace
it with the BBX. As proposed, the BBX will include an electronic trading system
to allow order negotiation and automatic execution. The NASDAQ Stock Market has
indicated its belief that the BBX will bring increased speed and reliability to
trade execution, as well as improve the overall transparency of the marketplace.
Specific criteria for listing on the BBX have not yet been announced, and the
BBX may provide for listing criteria which the Company may not meet. If the OTC
Bulletin Board is phased out and the Company does not meet the criteria
established by the BBX, there may be no transparent market on which the
Company's securities may be included. In that event, investors may have
difficulty buying and selling the Company's securities.

SIX MONTHS ENDED JUNE 30, 2002 COMPARED WITH THE SIX MONTHS ENDED JUNE 30, 2001

         During the six months ended June 30, 2002 the Company incurred general,
administrative and consulting expenses in the amount of $319,979 as compared to
$1,925 for the same period ended June 30, 2001. The Company has incurred these
expenses in connection with its aggressive strategy to seek an acquisition
candidate. During the six months ended June 30, 2002, the Company incurred
payroll costs of $144,566, consulting fees of $87,871, travel and entertainment
costs of $8,549, interest on outstanding debentures of $6,286, and professional
fees of $62,575.

THREE MONTHS ENDED JUNE 30, 2002 COMPARED WITH THE THREE MONTHS ENDED
JUNE 30, 2001

         During the three months ended June 30, 2002 the Company incurred
general, administrative and consulting expenses in the amount of $146,709 as
compared to $367 for the same period ended June 30, 2001. The Company has
incurred these expenses in connection with its aggressive strategy to seek an
acquisition candidate. During the three months ended June 30, 2002, the Company
incurred payroll costs of $49,418 consulting fees of $46,505, interest on
outstanding debentures of $3,143, and professional fees of $45,038.

Liquidity

         The Company has financed its operations through advances from its
President and from the sale of convertible debentures. During October and
November 2001 the Company sold an aggregate of $11,475 of the Company's 5%
senior subordinated convertible debentures due December 31, 2002. The debentures
are convertible into the Company's Common Stock at $.001 per share.

                                       12
<PAGE>

         On November 30, 2001, the Company authorized the issuance of 8%
subordinated convertible debentures due June 30, 2003 in the aggregate amount of
$500,000. These debentures are convertible into the Company's Common Sock at
$.50 per share. As of June 30, 2002 the Company sold an aggregate of $150,000 of
these debentures.

         At June 30, 2002 the Company had $174 in cash and total assets of
$1,965. As of that same date the Company had total current liabilities of
$380,961, and had a working capital deficit of $380,599.

         As of June 30, 2002 the Company's total liabilities, including
non-current liabilities were $530,961 and the Company had a stockholders'
deficit of $528,996.

         The Company will attempt to improve liquidity and capital resources in
the short term by loans from related parties and private financing activities of
both the Company's equity and debt securities. There can be no assurance that
the Company will be successful in these efforts and if it does not address its
financing needs, it could no longer be viable.

                                       13
<PAGE>

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings.

         There are no legal proceedings against the Company and the Company is
         unaware of any proceedings contemplated against it.

Item 2.  Changes in Securities.

         None.

Item 3.  Defaults Upon Senior Securities.

         None.

Item 4.  Submission of Matters to a Vote of Security Holders.

         No matters were submitted to the security holders for a vote.

Item 5.  Other Information.

         Effective June 10, 2002, Mr. Kenneth O'Rorke, the Company's Chief
         Financial Officer, tendered his resignation to the Company. In
         connection with his resignation, the Company agreed to issue Mr.
         O'Rorke twenty-five thousand (25,000) shares of the Company's Common
         Stock and a stock option exercisable for three (3) years to purchase
         125,000 shares of the Company's Common Stock at a cost of $1.50 per
         share. The issuance of the shares and option is contingent upon the
         Company's acquisition of certain assets from an unrelated third party.

Item 6.  Exhibits and Reports on Form 8-K.

         (a)      Exhibits

                  99.1     Certification pursuant to 18 U.S.C. Section 1350 by
                           the Company's Chief Executive Officer

                  99.2     Certification pursuant to 18 U.S.C. Section 1350 by
                           the Company's Chief Financial Officer

         (b)      Reports on Form 8-K.

                  None.
                                       14
<PAGE>

                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                                  MALACOLOGY, INC.


Dated:   August 14, 2002
                                                  By:   /s/ Vivek R. Rao
                                                     --------------------------
                                                     Vivek R. Rao
                                                     Chief Executive Officer

                                       15